- Medical School - UT Southwestern Medical School (2002-2006)
- Internship - UT Southwestern/Children's Medical Center (2006-2007), Pediatrics
- Residency - UT Southwestern/Children's Medical Center (2007-2009), Pediatrics
- Fellowship - UT Southwestern/Children's Medical Center (2010-2013), Pediatric Hematology/oncology
Kenneth S. Chen, M.D., is an Assistant Professor of Pediatrics at UT Southwestern, and an Attending Physician in the Gill Center for Cancer and Blood Disorders at Children’s Medical Center in Dallas, TX.
He received his B.S.E. in biomedical engineering from Johns Hopkins University and M.D. from UT Southwestern. He then completed a pediatric residency and pediatric hematology-oncology fellowship at UT Southwestern, where he joined the laboratory of James F. Amatruda.
As a physician-scientist, he divides his time between his research laboratory and Children’s Medical Center in Dallas, where he specializes in the care of children with cancer and blood disorders. His research interests in the laboratory focus on understanding the genetic drivers of childhood cancers, especially Wilms tumor and germ cell tumors, and new strategies for treating them.
In 2019 and 2020, Dr. Chen was named a Texas Monthly Super Doctor Rising Star.
- American Society of Pediatric Hematology and Oncology (2010)
- American Association for Cancer Research (2012)
- American Society of Hematology (2010)
- American Society of Clinical Oncology (2010)
- Texas Monthly Super Doctors, Rising Star 2020
- Texas Monthly Super Doctors, Rising Star 2019
- W.W. Caruth Scholar 2013, Childrens Medical Center Foundation
- Damon Runyon-Sohn Pediatric Cancer Fellow 2013
- First Place, Critical Appraisal of Literature 2008, Resident Section Poster Contest, Texas Pediatric Society
A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma.
Chen KS, Kwon WS, Kim J, Heo SJ, Kim HS, Kim HK, Kim SH, Lee WS, Chung HC, Rha SY, Hwang TH Cold Spring Harbor molecular case studies 2016 Sep 2 5 a000992
EGF Receptor and mTORC1 are novel therapeutic targets in nonseminomatous germ cell tumors.
Chen KS, Fustino NJ, Shukla AA, Stroup EK, Budhipramono A, Ateek C, Stuart SH, Yamaguchi K, Kapur P, Frazier AL, Lum L, Looijenga LHJ, Laetsch TW, Rakheja D, Amatruda JF Molecular cancer therapeutics 2018 Feb
DNA methylation analysis reveals distinct methylation signatures in pediatric germ cell tumors.
Amatruda JF, Ross JA, Christensen B, Fustino NJ, Chen KS, Hooten AJ, Nelson H, Kuriger JK, Rakheja D, Frazier AL, Poynter JN BMC cancer 2013 13 1 313
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.
Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA Blood 2001 May 97 10 3146-51
A large T cell invagination with CD2 enrichment resets receptor engagement in the immunological synapse.
Singleton K, Parvaze N, Dama KR, Chen KS, Jennings P, Purtic B, Sjaastad MD, Gilpin C, Davis MM, Wülfing C Journal of immunology (Baltimore, Md. : 1950) 2006 Oct 177 7 4402-13
Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides.
Chen KS, Bach A, Shoup A, Winick NJ Pediatric blood & cancer 2013 Jun
Chen KS, Stroup EK, Budhipramono A, Rakheja D, Nichols-Vinueza D, Xu L, Stuart SH, Shukla AA, Fraire C, Mendell JT, Amatruda JF Genes & development 2018 Jul
p53 genes function to restrain mobile elements.
Wylie A, Jones AE, D'Brot A, Lu WJ, Kurtz P, Moran JV, Rakheja D, Chen KS, Hammer RE, Comerford SA, Amatruda JF, Abrams JM Genes & development 2015 Dec
Hemolytic non-uremic syndrome.
Chen KS, Neunert CE, Crary SE, Buchanan GR Pediatric blood & cancer 2012 Jul 59 1 167-9
Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours.
Rakheja D, Chen KS, Liu Y, Shukla AA, Schmid V, Chang TC, Khokhar S, Wickiser JE, Karandikar NJ, Malter JS, Mendell JT, Amatruda JF Nature communications 2014 2 4802
A big catch for germ cell tumour research.
Chen KS, Amatruda JF PLoS genetics 2013 Apr 9 4 e1003481
Invited reply to amikacin ototoxicity in children with cancer: the problem is the administration schedule.
Chen K, Bach A, Shoup A, Winick N Pediatric blood & cancer 2014 Feb 61 2 191
- A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma.
- Wilms tumor
- Germ cell tumors